This page was printed from the Northern & Eastern Devon Formulary and Referral site at
Please ensure you are using the current version of this document
Prednisolone 10mg/ml oral solution 30ml bottle has been added into the formulary for patients unable to use standard tablets when total treatment exceeds 150mg. Please see the formulary for further information.
Vensir® XL and Venlablue® XL have been removed as the preferred brands of venlafaxine m/r capsules. Please see the formulary for more information.
Glucodrate® oral powder sachets have been added into the formulary only for patients with short bowel syndrome who are unable to tolerate St Mark's Electrolyte Solution.
NovoRapid PumpCart® insulin aspart 100 units per 1ml, 1.6ml cartridges has been added into the formulary. Please see the formulary for further information.
Diagnostic and monitoring devices for diabetes mellitus: was reviewed and has been refreshed and expanded to include additional information from NICE guideline NG17 (Type 1 diabetes in adults: diagnosis and management). Please see the formulary for further information.
Continence (Chapter 18): has been reviewed following consultation with specialists and the chapter has been refreshed, updated with relevant products, advice, and quick guides. Please see the formulary for further information.
NICE TA420 Ticagrelor for preventing atherothrombotic events after myocardial infarction was published in December. The TA recommends treatment with ticagrelor for a maximum of 3 years for patients who have had an MI and who are at high risk of a further event after the initial 12 months of ticagrelor 90mg twice daily or other ADP receptor inhibitor treatment (prasugrel or ticlopidine). The formulary advice has been amended to define those patients at high risk, please see the formulary for further information.
Rosacea guidance: Following the addition of ivermectin to the formulary as a treatment option for rosacea the formulary guidance has been reviewed, with consultation from local specialists. Please see the formulary for up to date guidance.
Braltus® (tiotropium) inhalation powder capsules (£25.50) have been added into the formulary as a less costly alternative to Spiriva® inhalation powder capsules (£33.50), which has been removed. Please see the formulary for further information.
Darifenacin has been added into the formulary as an alternative anti-muscarinic urinary antispasmodic drug. Please see the formulary for further information.
Thick and Easy® and Thick and Easy® Clear have been approved to be added to the formulary. These will be added with some guidance notes on their use, patients should remain on the products recommended and not switched between the two. Also the sachet preparations should not be prescribed as they are significantly more expensive. Please see the formulary for further information.
Pramipexole MR has been added into the formulary alongside the standard release preparation. Pipexus® MR is the preferred brand to be prescribed. Please see the formulary for further information.
Cholurso®has been added into the formulary as the preferred brand of ursodeoxycholic acid. This is only for the 250mg preparation. If a patient requires a higher dose, multiples of the 250mg tablet is less costly. Please see the formulary for further information.
Asthma guidance: Both the adult and the paediatric guidance for the management of asthma have been reviewed.
Vitamin D: Public Health England revised its recommendation on vitamin D. Sections of the formulary guidance for the management of vitamin D deficiency have been revised to reflect the new recommendations (see here). The guidance also highlights that multivitamin preparations which contain vitamin D are available over-the-counter from pharmacies and supermarkets.
Menopause guidance: The formulary guidance on menopause and HRT has been reviewed using NICE guidance publication (NG23 Menopause: diagnosis and management) and the British Menopause Society guidance.See here for the formulary guidance.